Pilot comparison of 18F-fluorocholine and 18F- fluorodeoxyglucose PET/CT with conventional imaging in prostate cancer

Journal of Medical Imaging and Radiation Oncology

Volumn 54, Issue 4, 2010, Pages 325-332

  Beauregard, J M ^a   Williams, S G ^a   Degrado, T R ^b   Roselt, P ^a   Hicks, R J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

18F Fluorocholine; 18F Fluorodeoxyglucose; cancer staging; positron emission tomography; prostate cancer

Indexed keywords

FLUOROCHOLINE F 18; FLUORODEOXYGLUCOSE F 18; FUROSEMIDE; PREDNISOLONE; TRACER; UNCLASSIFIED DRUG; CHOLINE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FLUOROCHOLINE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE SCINTISCANNING; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DATA EXTRACTION; HUMAN; MALE; MEDICAL INFORMATION SYSTEM; MEDICAL RECORD; MOLECULAR PROBE; MULTIMODALITY CANCER THERAPY; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; EVALUATION; FOLLOW UP; IMAGE QUALITY; METHODOLOGY; MIDDLE AGED; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROSTATE; PROSTATE TUMOR; RADIOGRAPHY; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

AGED; CHOLINE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; PROSTATE; PROSTATIC NEOPLASMS; RADIOGRAPHIC IMAGE ENHANCEMENT; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77955789181     PISSN: 17549477     EISSN: 17549485     Source Type: Journal    
DOI: 10.1111/j.1754-9485.2010.02178.x     Document Type: Article

References (22)

1. Williams SG, Millar JL, Dally MJ, Sia S, Miles W, Duchesne GM. What defines intermediate-risk prostate cancer? Variability in published prognostic models. Int J Radiat Oncol Biol Phys 2004 58 (1 11 8.
2. Oesterling JE, Martin SK, Bergstralh EJ, Lowe FC. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 1993 269 (1 57 60.
3. Platt JF, Bree RL, Schwab RE. The accuracy of CT in the staging of carcinoma of the prostate. AJR Am J Roentgenol 1987 149 (2 315 8.
4. Engeler CE, Wasserman NF, Zhang G. Preoperative assessment of prostatic carcinoma by computerized tomography. Weaknesses and new perspectives. Urology 1992 40 (4 346 50.
5. Oyama N, Akino H, Kanamaru H et al. 11C-acetate PET imaging of prostate cancer. J Nucl Med 2002 43 (2 181 6.
6. 18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy. BJU Int 2007 99 (6 1415 20.
7. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 1998 39 (6 990 5.
8. de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ. 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 2003 44 (1 32 8 discussion 38-9.
9. de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ. Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl Med 2003 44 (3 331 5.
10. 18F]fluorodeoxyglucose-positron emission tomography. J Urol 2003 169 (4 1337 40.
11. Rinnab L, Mottaghy FM, Blumstein NM et al. Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int 2007 100 (4 786 93.
12. Cimitan M, Bortolus R, Morassut S et al. [(18)F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 2006 33 (12 1387 98.
13. Schmid DT, John H, Zweifel R et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology 2005 235 (2 623 8.
14. 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res 2001 61 (1 110 7.
15. Heinisch M, Dirisamer A, Loidl W et al. Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml? Mol Imaging Biol 2006 8 (1 43 8.
16. Husarik DB, Miralbell R, Dubs M et al. Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging 2008 35 (2 253 63.
17. 18F] fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol 2002 168 (1 273 80.
18. Even-Sapir E, Keidar Z, Bar-Shalom R. Hybrid imaging (SPECT/CT and PET/CT)-improving the diagnostic accuracy of functional/metabolic and anatomic imaging. Semin Nucl Med 2009 39 (4 264 75.
19. Salminen E, Hogg A, Binns D, Frydenberg M, Hicks R. Investigations with FDG-PET scanning in prostate cancer show limited value for clinical practice. Acta Oncol 2002 41 (5 425 9.
20. Hricak H, Choyke PL, Eberhardt SC, Leibel SA, Scardino PT. Imaging prostate cancer: a multidisciplinary perspective. Radiology 2007 243 (1 28 53.
21. Harisinghani MG, Barentsz J, Hahn PF et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003 348 (25 2491 9.
22. Lowe VJ, Hoffman JM, DeLong DM, Patz EF, Coleman RE. Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. J Nucl Med 1994 35 (11 1771 6.